Growth Factor Gene-Modified Mesenchymal Stem Cells in Tissue Regeneration

This article was published in the following Dove Press journal:
Drug Design, Development and Therapy

Wen-Bo Nie
Dan Zhang
Li-Sheng Wang
Department of Rehabilitation Sciences, School of Nursing, Jilin University, Changchun, People’s Republic of China

Abstract: There have been marked changes in the field of stem cell therapeutics in recent years, with many clinical trials having been conducted to date in an effort to treat myriad diseases. Mesenchymal stem cells (MSCs) are the cell type most frequently utilized in stem cell therapeutic and tissue regenerative strategies, and have been used with excellent safety to date. Unfortunately, these MSCs have limited ability to engraft and survive, reducing their clinical utility. MSCs are able to secrete growth factors that can support the regeneration of tissues, and engineering MSCs to express such growth factors can improve their survival, proliferation, differentiation, and tissue reconstructing abilities. As such, it is likely that such genetically modified MSCs may represent the next stage of regenerative therapy. Indeed, increasing volumes of preclinical research suggests that such modified MSCs expressing growth factors can effectively treat many forms of tissue damage. In the present review, we survey recent approaches to producing and utilizing growth factor gene-modified MSCs in the context of tissue repair and discuss its prospects for clinical application.

Keywords: growth factor, mesenchymal stem cell, tissue regeneration, genetic engineering

Background

In settings where the human body is unable to partially or fully heal a given tissue injury, the use of stem-cell based regenerative therapies offers great promise as a means of improving patient outcomes. Indeed, such therapies can support heart or kidney transplants, bone reconstruction, or the repair of skin, cartilage, and neurons. In patients suffering from pathological conditions, such therapies can also potentially restore compromised tissue function. Mesenchymal stem cells (MSCs) are a form of multipotent stem cell capable of differentiating into a subset of distinct cell types such as myocytes, adipocytes, chondrocytes, and osteoblasts. As they are capable of differentiating into several cell types, homing to target tissues, and secreting growth factors and immunomodulatory compounds, MSCs represent an ideal cell type to use for treating a range of disease types. Importantly, these cells can also be easily obtained and amplified in vitro without engendering substantial ethical concerns, allowing them to be safely and readily used in patients.

Most organs in human adults are limited in their ability to undergo tissue regeneration, instead undergoing scarring that can disrupt organ function. As such, the utilization of MSCs to facilitate true tissue reconstruction rather than scarring represents an ideal means of maintaining normal tissue function in the context of injury. Many studies to date have explored the ability of MSCs to support bone development, restoration of ventricular functional, and improved renal tubular.
function in vivo and in clinical settings.\(^4\)–\(^6\) Unfortunately, however, these cells are limited in their therapeutic efficacy, particularly in contexts where injuries or the associated ischemic damage are severe and irreversible. Indeed, preclinical animal models suggest that MSCs have a poor ability to engraft, and they are also hampered by limited homing and survival in vivo owing to factors including inflammation, ischemia, and anoikis.\(^7\) One strategy proposed to overcome such limitations centers on the use of MSCs engineered to express specific genes.

Growth factors (GFs) are well known to be key mediators that can support MSC survival and proliferation, in addition to being key drivers of tissue regenerative processes. Many recent studies have utilized MSCs in order to deliver specific GFs to a target site of tissue regeneration either via utilizing cells naturally secreting these factors, or by engineering these cells to overexpress GFs of interest. Indeed, many recent studies have explored the therapeutic potential of MSCs engineered to express particular GFs in a therapeutic context. In the present review, we offer an overview of recent studies exploring the application of GF gene-modified MSCs in the field of tissue repair and reconstruction.

**The Relationship Between MSC Biology and GF Secretion**

MSCs are a readily isolated cell type that expand rapidly in culture without losing the ability to undergo self-renewal, permitting their use for reconstructing damaged tissues and organs via extensive amplification.\(^8\) In addition to their multipotent ability to differentiate into a range of cell types, MSCs can orchestrate and enhance proximal or distal cell functionality via paracrine signaling and endocrine mechanisms. Studies have shown MSCs to be capable of promoting tissue regeneration via secreting exosomes and GFs including hepatocyte growth factor (HGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF).\(^9\) Additionally, these cells express high levels of factors known to regulate hematopoietic cell function such as CXCL12, vascular cell adhesion molecule 1, interleukin-7, angiopoietin-1 (Ang-1), and osteopontin.\(^10\) Consistent with these findings, in vivo studies also support the fact that the paracrine secretion of GFs by MSCs is a key mechanism whereby they support target tissue healing, as while these cells can migrate to sites of injury, the cells derived therefrom contribute only to a limited degree to therapeutic efficacy. Many recent studies have suggested that the secretion of GFs and other bioactive molecules may be one of the primary mechanisms whereby MSCs mediate their therapeutic efficacy. These secreted compounds can inhibit a range of processes such as apoptotic cell death and fibrosis,\(^11\) in addition to being able to drive angiogenesis,\(^12,13\) and to regulate the immune response.\(^14,15\)

Without any exogenous manipulation, MSCs achieve limited therapeutic efficacy due to their poor survival and limited GF secretion upon transplantation. The therapeutic efficacy of MSCs ultimately depend upon the number of cells implanted, the function of these cells, when they are administered, and what condition they are being used to treat.\(^9,16\)–\(^18\) Poor MSC engraftment can be attributable to limited cell survival as a consequence of ischemia, anoikis, loss of trophic factors, or localized inflammation.\(^19\) It is thus vital that MSC survival and differentiation be improved following transplantation in order to enhance therapeutic outcomes in treated patients. To that end, studies have explored the use of MSCs modified to express certain exogenous genes that can enhance their ability to promote angiogenesis and target tissue homing.\(^13,20\) These genetically engineered MSCs can thereby both improve MSC engraftment and functionality, while also allowing for the targeted delivery of therapeutic gene products that can enhance local tissue healing.\(^21\) Indeed, MSCs can secret a broad profile of active molecules including hematopoietic growth factors, angiogenic growth factors, trophic molecules, immunomodulatory cytokines, and chemokines. The best-characterized GFs and cytokines produced by these cells are compiled in Table 1. Based on these previous findings, it is clear that engineering MSCs to overexpress GFs may be an optimal means of improving the therapeutic efficacy of these cells.

**Vectors Used for GF Overexpression in MSCs**

Both non-viral vectors such as lipids or polymers, as well as viral vectors (including retroviruses, adenoviruses, lentiviruses and adeno-associated viruses) have been used to mediate GF overexpression in MSCs. The most common vectors used for such approaches are compiled in Table 2.\(^31\)–\(^39\) Using viral vectors to insert genes into MSCs is a high transduction efficiency approach that has the potential to induce off-target effects owing to insertional mutagenesis.\(^32,35,40,41\) Viral systems are also limited by relatively small transgene cargo capacity, high production cost, difficulties in production and scale-up, and adverse
immune reactions. There are advantages and disadvantages to all known viral vectors, with the selection of an appropriate vector being dependent upon transduction rates and the desired duration of treatment and target gene expression. It is also essential that such modified MSCs be extensively screened for safety reasons, thus potentially reducing the cost-effectiveness of such approaches in a clinical context.

To avoid the limitations of viral vectors, non-viral vectors such as nanoparticles (NPs) or cationic liposomes have been utilized to deliver vectors into MSCs. These alternative delivery strategies are more scalable and flexible, easier to synthesize and target to tissues, less likely to drive immune stimulation, and more amenable to scale-up manufacturing. However, the disadvantages of non-viral vectors can include their transient expression with low efficiencies, and their potential for associated toxicity. He et al. utilized the cationic polymer pullulan-spermine to overexpress HGF encoded in the pMEX vector in MSCs, resulting in high in vitro HGF expression. In contrast to such success, however, Tan et al. found that such plasmid-containing liposomes were only able to mediate FGF expression in BMSCs at a relatively low transfection efficiency, although they were able to achieve expression at levels sufficient to support periodontal regeneration. Still other authors have utilized lipid-based NPs to achieve target gene expression in MSCs for a sustained period of time. These vectors, however, have recently been suggested to have the potential to induce genotoxicity, thus potentially mediating oncogenesis. It is thus important to weight the relative costs and benefits of these different strategies to MSC engineering in order to produce a safe, effective, and sustainable approach for clinical use.

### The Impact of GF Overexpression on MSCs in Tissue Regeneration

#### The Primary Impact of GF Gene-Modified MSCs in Tissue Regeneration

Many previous studies have explored the ability of GFs to regulate MSC growth in vitro via adding these GFs to cell culture media and/or by inhibiting their cognate receptors, allowing for the study of concentration-dependent effects. When MSCs are treated with GFs including FGF-2, PDGF-B, TGF-β1, and VEGF-A, this has been shown to result in enhanced production and secretion of GFs by MSCs. As such, overexpressing target GFs in MSCs may be able to yield similar therapeutic effects to those observed upon adding recombinant GFs to MSC cultures, although they can also affect the biology of cells in a therapeutically uncertain manner. Indeed, the secretion of exosomes and GFs such as HGF, FGF-B, and VEGF is potentially key to the regenerative abilities of MSCs. When these GFs are overexpressed, this is associated with significant enhancement of MSC-mediated regeneration of tissues, making

### Table 1 Secretome of Mesenchymal Stem Cells

| Type of Secreted Factors | Active Molecules | Ref |
|--------------------------|------------------|-----|
| Hematopoietic growth factors | SCF, FLT3LG, Thrombopoietin, IL-3, IL-6, GM-CSF, M-CSF | [22–24] |
| Angiogenic growth factors | HGF, VEGF, Angiopoietin, PDGF, IGF-1, FGF-2, FGF-4, FGF-7 | [22,23,25,26] |
| Trophic molecules | Adiponectin, Adrenomedullin, Osteoprotegerin, MMP10, MMP13, TIMP-1, TIMP-2, TIMP-3, TIMP-4, Leptin, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, BDNF, GDNF, NGF, PIGF | [22,23,27] |
| Immunomodulatory cytokines | IL-1α, IL-1β, IL-2, TSG-6, OSM, IL-7, IL-10, IL-11, IL-12, IL-13, IL-16, IFN-γ, TNF-α, LIF, TGF-β, MGF | [23,24,28] |
| Chemokines | CCL1, CCL2, CCL5, CCL8, CCL11, CCL16, CCL18, CCL22, CCL23, CCL24, CCL26, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, CXCL11, CXCL12, CXCL13, CX3CL1, XCL1 | [22,23,29,30] |

**Abbreviations:** SCF, stem cell factor; FLT3LG, Fms-related tyrosine kinase 3 ligand; IL, interleukin; GM-CSF, granulocyte macrophage colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factors; PDGF, platelet-derived growth factor; IGF, insulin-like growth factor; FGF, fibroblast growth factor; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; IGFBP, insulin-like growth factor-binding protein; BDNF, brain-derived neurotrophic factor; GDNF, glial cell-derived neurotrophic factor; NGF, nerve growth factor; PIGF, placenta growth factor; TSG, tumor necrosis factor-stimulated gene; OSM, oncostatin; IFN, interferon; TNF, tumor necrosis factor; LIF, leukemia inhibitory factor; TGF, transforming growth factor; MGF, macrophage migration inhibitory factor; CCL, C-C motif chemokine ligand; CXCL, C-X-C motif chemokine ligand; CX3CL, C-X3-C motif chemokine ligand; XCL, X-C motif chemokine ligand.
such GF overexpression strategies a focus of key therapeutic interest. A general overview of the therapeutic utilization of GF gene-modified MSCs is shown in Figure 1. First, MSCs are extracted from humans or animals, identified, and amplified. Second, the GF gene of interest is integrated into the vector and jointly introduced into the MSCs. Third, GF modified MSCs are delivered to the target tissues of the recipient organism wherein they can play a therapeutic role via secreting GFs, promoting angiogenesis, and enhancing homing functions.

### The Selection of GFs in MSC Modification

Initially selection of GFs used to treat MSCs was based on prior understanding of the role of these GFs in cellular differentiation and morphogenesis, with experiments being aimed at exploring the ability of these GFs to drive MSC differentiation towards particular lineages. For example, HGF is a multifunctional factor produced by MSCs which can bind to its cognate receptor c-Met on cells of the vascular endothelium. Studies using mice lacking expression of HGF in specific tissues highlighted the ability of this GF to support tissue repair and regeneration, and the implantation of MSCs overexpressing HGF led to enhanced left ventricular remodeling, reductions in neurological deficits, and enhanced liver function. Similarly, MSCs engineered to overexpress VEGF have been shown to enhance the viability of cells in the context of in vitro hypoxia and can also improve capillary formation in animal models of myocardial infarction, hind limb ischemia, and skin defects. Certain GFs exhibit similar repair effects in MSCs for many tissue types. For instance, angiopoietin-1 (Ang-1) is a growth factor that specifically acts on endothelial cells and can drive angiogenesis. MSCs overexpressing Ang-1 have been shown to inhibit cardiac remodeling and to drive improved myocardial angiogenesis and arteriogenesis relative to

### Table 2 Summary of Common Vectors Used for GF Expression in MSCs

| Types of Vectors | Commonly Used Examples | Transduction Efficiency in MSCs | Advantages | Disadvantages | Preclinical or Clinical Application | Ref |
|------------------|------------------------|---------------------------------|------------|--------------|-------------------------------------|-----|
| Viral vector      | Retrovirus             | 74.8–85.6%                      | Long-term stable gene expression | Insertional mutagenesis and activation of oncogenes | Preclinical | [32] |
|                  | Adenovirus             | 76.2–80%                        | Lower risk of genotoxicity | Transient gene expression | Preclinical | [35] |
|                  | Lentivirus             | 96.3–99.1%                      | Long-term stable gene expression | Insertional mutagenesis | Clinical | [32] |
|                  | Adeno-associated virus | ≥ 65%                           | Long-term gene expression; non-immunogenic | Limited transport capacity | Preclinical | [36] |
| Nonviral vector   | Physical methods       |                                 |            |              |                                     |     |
|                  | Electroporation        | 68.0–80.0%                      | Moderate transfection efficiency | Low cell viability | Preclinical | [34,37] |
|                  | Nucleofection          | 51.0–88.0%                      | Moderate/High transfection efficiency | Low cell viability | Preclinical | [34,38] |
| Chemical methods  | Lipid and polymeric agents | 2.0–35.0%                      | Low immunogenicity | Low transfection levels, cytotoxic | Preclinical | [33,38] |
|                  | Dendrimers             | 10.0–17.0%                      | Low cytotoxicity and immunogenicity | Low transfection levels | Clinical | [33,39] |
|                  | Inorganic nanoparticles | 25.0–75.0%                      | Wider availability, controlled delivery, low toxicity | Only moderate transfection efficiencies | Preclinical | [31,33] |

Abbreviations: GF, growth factor; MSC, Mesenchymal stem cell; Ref, references.

Nie et al. Dovepress submit your manuscript | www.dovepress.com
DovePress Drug Design, Development and Therapy 2020:14
1244
control MSCs. Such cells were also able to markedly reduce pulmonary inflammation and to facilitate tissue repair. MSCs overexpressing Ang-1 have also been shown to improve wound healing in a rat model system, enhancing angiogenesis in addition to dermal and epidermal tissue regeneration. Tissue-specific repair factor modifications enhance the repair capabilities of MSCs in specific tissues. For example, BDNF promotes the survival and differentiation of neuronal tissue by acting on receptor kinases, and BDNF-MSCs have primarily been used to promote the survival of neurons in the context of brain injury. Similarly, TGF family proteins are closely linked to MSC survival and differentiation. In particular, TGF-β superfamily genes are often used to drive MSC chondrogenic differentiation. Therefore, TGF-β1 has been chosen to engineer rat MSCs to support enhanced regeneration of cartilage. Hence, the selection of a particular GF for use in the modification of MSCs depends upon the effect of growth factors on MSCs and also on the response of the damaged tissue itself.

MSCs Overexpressing Multiple GF Genes Exhibit Therapeutic Utility

The primary mechanism whereby such gene-modified MSCs contribute to tissue repair is via the secretion of these multifactorial GFs rather than via their ability to differentiate into particular cell types, with these cells serving key roles in inhibiting fibrosis and inflammation while promoting angiogenesis. Some studies have modified MSCs to express multiple synergistic genes in an effort to enhance their therapeutic utility. For example, IGF-1 is a GF that promotes cell survival, whereas HGF promotes angiogenesis while suppressing inflammation.- In a rat model of myocardial infarction, human adipose-derived stem cells that continuously produced IGF-1 and HGF were able to achieve a 1.3-fold increase in medium-sized blood vessel density at the infarct border zone relative to control cells. In another study using a porcine model of myocardial infarction, such MSCs overexpressing HGF and IGF-1 were able to drive angiogenesis and suppress

---

**Figure 1** An overview of the therapeutic utilization of GF gene-modified MSCs.

**Abbreviation:** GF, growth factor; MSC, Mesenchymal stem cell.
inflammation more effectively than other cells, although these cells also exhibited enhanced fibrosis suggesting that combined IGF-1 and HGF exposure over extended periods of time can induce both beneficial and counterproductive effects. This suggests that the preparation of MSCs secreting both IGF-1 and HGF may not be an effective means of synergistically effective cardiac repair, with the elevated levels of either factor in the local environment potentially contributing to this effect.

The Role of Exosomes Derived from GF-Modified MSCs in Tissue Regeneration

Multiple studies have indicated a role for MSCs in regenerative medicine through their paracrine effects and ability to produce exosomes. Encapsulated with a lipid bilayer, exosomes can protect their contents from degradation and can transport a variety of small biomolecules including mRNAs, miRNAs, and proteins to surrounding cells. Moreover, MSC sources and culture conditions have been shown to influence the regenerative responses induced by exosomes, as a number of GFs can be detected in MSC-derived exosomes, including HGF, IGF family members, FGF2, and platelet-derived growth factor-AA (PDGF-AA). As natural vesicles suitable for gene delivery, MSC-derived exosomes exhibit a broad range of therapeutic effects, and can mediate tissue repair, immunological regulation, and inflammatory control. Moreover, recent studies have revealed that MSC-derived exosomes can mediate therapeutic benefits in animal disease models, with previous studies of bone fracture, cutaneous wound, myocardial infarction, and acute hepatic injury all having demonstrated the clinical utility of such exosomes. Exosomes can modulate the differentiation and migration of MSCs in a targeted manner, offering an opportunity to promote tissue regeneration in a cell-free manner. Genetic manipulation can also be used to control the levels of such GFs in these exosomes, as in studies in which hucMSCs were engineered to secrete GFs in a controlled fashion over an extended period. Such genetically modified MSC-derived exosomes may thereby be able to mediate tissue regenerative benefits, making them ideal for future therapeutic regenerative regimens.

Preclinical Use of GF-Modified MSCs in Tissue Regeneration

The therapeutic value of MSCs stems largely from their ability to mediate angiogenesis and tissue regeneration, secreting GFs and exosomes to achieve therapeutic efficacy and homing to target tissue sites. A number of preclinical studies to date have sought to use genetically-modified MSCs that secrete GFs in order to treat a wide range of conditions associated with tissue injuries. A detailed overview of the uses of GF-modified MSCs in preclinical tissue repair studies is given in Table 3.

Central Nervous System (CNS) Lesions

Occlusive cerebrovascular diseases can result in cerebral ischemia and significant neuropathology, leading to the exploration of many modes of treating such diseases including the application of MSC-based therapies. One of the keys to treating CNS lesions is to maintain the integrity of the blood-brain barrier and to reduce edema in the context of ischemia, thus reducing the severity of injury. Importantly, MSCs can home to the CNS in vivo, allowing them to improve functional recovery following stroke owing to their ability to drive angiogenesis and neurogenesis while suppressing local inflammation via GF and chemokine secretion. MSCs overexpressing specific GFs can also help to facilitate efficient CNS tissue regeneration. For example, MSCs overexpressing HGF have shown superior efficacy in reducing neurological deficits in the rat middle cerebral artery occlusion (MCAO) model relative to unmodified MSCs. Su et al found that BMSCs engineered to overexpress GDNF using a lentivirus were able to protect against injury in PC12 cells, highlighting their potential therapeutic value in the context of Parkinson’s disease. However, there are still many obstacles to the widespread use of this technique in CNS lesions. Intracerebral injection remains particularly difficult if the lesions are widespread and numerous. In addition, intra-arterial injection will increase risk of embolic events and intravenous injections typically result in few cells reaching the target sites.

Ischemic Heart Disease (IHD)

In many nations, the primary cause of morbidity and mortality is myocardial infarction (MI), and as such it is one of the most common targets of therapeutic efforts to engineer MSCs to facilitate tissue repair. Indeed, a number of genes have been proposed as targets for MSC-mediated delivery in the context of MI including HO-1, IGF-1, Ang-1, SVV, Bcl-2 and Akt1. Over 30 clinical studies to date have been registered using MSCs for the treatment of MI, but these studies have suggested the need for improved therapeutic efficacy of these MSCs. Angiogenesis mediates clinical benefits via the formation, remodeling, and maturation of blood vessels in injured tissues, making GF engineering an ideal
| Disease                      | Therapeutic Modification | Vector Type          | Cell Type       | Cell Counts/ per Animal | Method of Administration | Effects                                                                 | Ref   |
|------------------------------|-------------------------|----------------------|-----------------|------------------------|--------------------------|--------------------------------------------------------------------------|-------|
| Transient MCAO              | FGF-2                   | Replication-incompetent HSV-1 vector | Rat BMSC       | $1 \times 10^6$/Rats  | Administered intracerebrally | Enhanced survival, reduced infarction volume, improve functional recovery | [76]  |
| Transient MCAO              | BDNF                    | Adenoviral vector    | Human MSC       | $5 \times 10^5$/Rat    | Intracerebrally injection | Promotes the survival and differentiation, reduced infarct size         | [63]  |
| Transient MCAO              | HGF                     | Multimutated herpes simplex virus type-1 vector | Rat BMSC       | $1 \times 10^5$/Rat    | Injected into the right striatum | Improved neurological deficits, reduced infarction volume               | [53]  |
| Huntington's disease         | BDNF                    | Lentiviral vector    | Human BMSC      | $5 \times 10^5$ cells per hemisphere/ Mouse | Injected bilaterally into the striata with vehicle | Decreased striatal atrophy, reduced anxiety, induced increase in neurogenesis-like activity. | [77]  |
| Parkinson's disease          | BDNF                    | Electroporation      | Rat BMSC       | $5 \times 10^5$/Rat    | Lateral ventricular injection | Reduce the DA metabolic rate, improve the level of DA, and improve the behavior of PD rats | [78]  |
| Traumatic Brain Injury       | BDNF                    | Adenoviral vector    | Rat BMSC       | $1 \times 10^5$/Rat    | Intraventricular injection | Increased BDNF levels, attenuated neuronal injury                      | [62]  |
| Myocardial infarction        | VEGF                    | Bile acid-modified polyethyleneimine | Human BMSC     | $1 \times 10^5$/Rat    | Injected intramyocardially into the contracting wall bordering the infarct | Improved cell viability, enhanced capillary formation in the infarcted region, attenuated left ventricular remodeling | [54]  |
| Myocardial infarction        | HGF                     | Retroviral vector    | Rat BMSC       | $2 \times 10^5$/Rat    | Injected into three points around the infarct area                      | Improved left ventricular function, decreased infarcted scar area, and increased angiogenesis. | [52]  |
| Acute myocardial infarction  | HGF and IGF-I           | Lentiviral vectors from adipose tissue (paMSC) | Pig MSC       | $50 \times 10^6$/Pig  | 7–8 injections surrounding the infarcted area                           | Reduced inflammation, promoted angiogenic processes | [69]  |
| Myocardial fibrosis          | HGF                     | Lentiviral vector    | Rat BMSC       | $2 \times 10^7$/Rat    | Injected into the border zone of infarcted heart tissue                | Enhance cell survival, improve cardiac function, stimulate angiogenesis, and reduce myocardial fibrosis | [79]  |
| Myocardial infarction        | VEGF                    | Adenovirus vector    | Rat BMSC       | $5 \times 10^5$/Rat    | Injected into the border zone surrounding the infarcted area           | Induced myocardial angiogenesis and cardiomyocyte regeneration, prevented progressive scar formation and heart dysfunction | [80]  |
| Disease                        | Therapeutic Modification | Vector                  | Cell Type | Cell Counts/ per Animal | Method of Administration                                      | Effects                                                                                           | Ref     |
|-------------------------------|--------------------------|-------------------------|-----------|-------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------------------------------|---------|
| Acute myocardial infarction   | Ang-1                    | Recombinant adenoviruses | Rat BMSC  | 5×10^6/Rat              | Injected into the border zone surrounding the infarct anteriorly and laterally | Increased capillary density and reduced infarct size                                               | [57]    |
| Ischemic myocardium          | Angiopoietin vector       | Rat BMSC                | 3×10^6/Rat | Injected into the ischemic myocardium | Induced differentiation, promoted angiogenesis, improved cardiac function |                                                                                  | [81]    |
| Myocardial infarction         | Survivin Lentiviral vector | Rat BMSC                | 2×10^6/Rat | Intra-myocardial injections | Increased capillary density reduced the infarct size, inhibited collagen deposition, and further improved cardiac function |                                                                                  | [82]    |
| Radiation-induced intestinal injury | HGF                        | Adenoviral vectors       | Human UC-MSCs | 2×10^6/Mouse | Injected intravenously via the tail vein | Improved intestinal histopathology, reduced inflammation, and increased the proliferation and decreased the apoptosis of intestinal epithelial cells. | [83]    |
| Radiation-wound injury       | PDGF-A and BD-2 adenoviruses | Rat BMSC                | 1×10^7/Rat | Injected into the wound bed and margin of the excisional wound. | Resulted in better granulation formation/maturation and skin appendage, promoted wound healing regeneration |                                                                                  | [84]    |
| Radiation-induced lung injury | TGF-β type II receptor adenoviral vector | Mouse BMSC | 5×10^5/Mouse | Intravenously injected | Attenuated early lung injury and improved survival and lung fibrosis |                                                                                  | [85]    |
| Radiation-induced liver injury | NGF Plasmid vector       | Mouse BMSC              | 5×10^10/Mouse | Intravenously injected | Inhibited the apoptosis of mouse hepatic cells induced by radiation, improved the survival rate of mice |                                                                                  | [86]    |
| Cartilage defects            | TGF-β1 Pullulan–spermine (nonviral gene vector) | Rat BMSC three-dimensional (3D) reverse transfection system | 1×10^6 cells per scaffold/Rat | TGF-β1 gene-transfected MSC seeded gelatin sponge was implanted to the full-thickness cartilage defect | Promoted chondrogenesis of MSCs, and improved cartilage regeneration. |                                                                                  | [42]    |
| Osteopenia                   | BMP-2 Adeno-associated virus | Mouse BMSC              | 1×10^4/Mouse | Intravenously injected | Increased bone mineral density and bone mineral content, promoted proliferative capabilities of cells |                                                                                  | [87]    |
| Limb ischemia                | VEGF Lentiviral vectors  | Human BMSC              | 1×10^4/Mouse | Injected into the tail vein | Induced the migration of endothelial cells and enhanced blood flow restoration |                                                                                  | [49]    |

(Continued)
means of achieved such angiogenic efficacy in a therapeutic setting. Moreover, among angiogenic growth factors, the HGF/Met pathway is a key mediator of cardiovascular remodeling following tissue injury, with HGF mediating the migration and expression of cardiac-specific markers in MSCs. Many studies have utilized murine, rat, and porcine models of MI to confirm the ability of such HGF-expressing MSCs to enhance cardiac function, drive angiogenesis, and decrease myocardial fibrosis. In addition, human BMSCs expressing HGF have been shown to have enhanced anti-arrhythmic properties. Following the delivery of these modified cells to the infarcted region, low local nutrient and oxygen levels can result in poor survival and engraftment efficiency. VEGF is known to enhance the survival of these and other cell types upon transplantation in damaged tissues. Normally, angiogenesis in the infarcted tissue is not sufficient to meet the needs of the remaining viable myocardial tissue, thereby compromising contractile compensation. Moon et al found that MSCs overexpressing VEGF were able to induce a 1.4-fold increase in VEGF expression upon hypoxic exposure relative to cells grown under normoxic conditions, and these modified MSCs were able to facilitate the enhanced microvascularization of infarcted myocardial tissues.

**Musculoskeletal Defects and Skin Injuries**

Bone, muscle, and skin are all highly metabolized tissues with a relatively high vascular supply, based on the homeostasis of biomaterial structures that need to be studied for
growth and remodeling. Kumar et al found that mice transplanted with MSCs engineered to overexpress bone morphogenetic protein 2 (BMP2) exhibited increased bone mineral density and content and improved BMSC proliferation relative to control animals, with a corresponding improvement in bone formation. Dental pulp stem cells overexpressing HGF have also been shown to prevent bone loss in the early phase of ovariectomy-induced osteoporosis. MSCs engineered to overexpress Ang-1 are also able to facilitate wound healing as well as dermal and epidermal regeneration and angiogenesis. In addition, tissue engineering is usually achieved via inserting stem cells into three-dimensional scaffolds that are induced to generate new cells. GF-modified MSCs have been widely used in this innovative treatment for musculoskeletal defects and skin wounds, with many studies having explored optimal tissue engineering approaches to improving the efficiency of cells, scaffolds, and bioactive factors. The most commonly studied technique is to add supplemental growth factors that locally provide signals that mimic the process of bone regeneration. It is therefore important to design systems that provide this biological cue in a time-controlled manner so as to mimic the normal bone healing process. 

Radiation Injury

Certain tissues including the lungs, intestines, and bone marrow are highly radiation sensitive. While hematopoietic stem cells can regenerate the bone marrow, strategies to mediate similar regeneration of lung and intestinal tissue are limited. GF-overexpressing MSCs may therefore represent an ideal approach to regenerating tissues following radiation injury and associated damage. For example, in a model of radiation-induced lung fibrosis, MSCs overexpressing HGF were shown to home to damaged lung tissue wherein they could promote epithelial cell proliferation and survival, thereby decreasing local inflammation and fibrosis. Similarly, MSCs engineered to overexpress TGF-β2 using an adeno viral vector were able to reduce lung injury and protect alveolar type II cells from radiation-induced apoptosis and DNA damage while reducing local inflammation, highlighting the benefits of GF production by MSCs in a paracrine manner. BMSCs engineered to express VEGF were similarly able to improve radiation-induced tissue injury repair owing to their ability to drive angiogenesis and regeneration of muscle fibers. BMSCs modified to express both BD2 and PDGF-A using an adenoviral vector were also able to improve wound healing in a model of radiation-induced wounding. MSCs overexpressing HGF suppress local inflammation and enhance small intestinal recovery in a murine model of radiation induced intestinal injury. Irradiation of cardiac tissue can result in late cardiovascular complications, and HGF can reduce such radiation-induced cardiac injury in a model of irradiation-induced heart disease. Adenoviral-mediated overexpression of HGF can also prevent radiation-induced hematopoietic damage and can reduce radiation induced hepatic damage in a rat model system.

Other Tissue Injuries and Diseases

In addition to the diseases mentioned above, MSCs modified to overexpress GFs have been employed to treat a wide range of tissue injuries and diseases in preclinical studies. Studies have shown that MSCs overexpressing HGF and Ang-1, respectively, can improve therapeutic outcomes in ischemia/reperfusion injury in the lung and in a Phosgene-induced model of lung injury owing to their ability to decrease pulmonary inflammation and endothelial permeability. Furthermore, MSCs modified to overexpress HGF have been shown to improve such AKI in a rat model of ischemia/reperfusion injury via reducing kidney inflammation and apoptotic cell death, thus making these cells of value to human therapeutic implementation. Moreover, MSCs expressing HGF can also enhance liver regeneration, making them viable for the treatment of those patients suffering from liver fibrosis or cirrhosis.

Clinical Trials Utilizing Genetically Modified MSCs

Given the number of preclinical studies demonstrating the potential utility of genetically modified MSCs, it is perhaps unsurprising that a number of clinical trials have been or are currently being conducted exploring the clinical value of such therapeutic approaches. To date over one thousand MSC-based trials have been conducted globally as reported in the US National Institute of Health database (ClinicalTrial.gov) in order to evaluate the safety and efficacy of either autologous or allogeneic MSCs. These trials are primarily focused on treating human diseases such as cancer, metabolic and inflammatory diseases such as chronic obstructive pulmonary disease, or adult respiratory distress syndrome. These studies are primarily reliant upon the use of unmodified MSCs for
these clinical efforts, with very few studies to date utilizing genetically modified MSCs. In 2006, Ripa et al published the results of a trial initiated in 2003 piloting the combination of VEGF gene therapy and stem cell mobilization in patients with severe chronic ischemic heart disease, finding this approach to be safe in humans. Another relevant study aims to explore the use of MSCs overexpressing BDNF for the treatment of Huntington’s disease (HD) patients in a pre-cellular therapy observational study. At present, however, this study has only enrolled a cohort of individuals early-stage HD in order to characterize their clinical and biomarker findings at baseline for comparisons to a planned future Phase 1 trial safety and tolerability trial applying these BDNF-modified MSCs. This trial has been submitted as an Investigational New Drug application to the Food and Drug Administration.

A number of challenges still face the clinical implementation of GF gene-modified MSC-based therapies. Of particular difficulty is the production of clinical grade therapeutic products, as such cellular and gene therapies differ from traditional pharmaceutical compounds, instead representing a form of heterogeneous biological product that can vary in response to a wide range of culture conditions. Modified MSCs also have the potential to become malignant upon transplant, and the use of recombinant viral vectors to manipulate these cells poses a significant safety concern. Minimizing variability in sample preparation while still remaining cost-effective thus represents a significant challenge. Therefore, the production of modified MSCs for clinical applications must comply with the Good Manufacturing Practice (GMP) standards for medicinal products. These recommended approaches include product safety, cell characterization, and manufacturing process control. Cell donors must be screened carefully and the stem cells expanded in the GMP production facilities should be tested using standardized procedures to assess their viability, sterility, genetic stability, tumorigenicity, adventitious agents, pyrogenicity, and mycoplasma infection status. Modified MSCs also have to be veriﬁed with respect to their identities, purity, stability and potency. In addition, the biological activity and toxicity of stem cell products must be tested in an applicable animal model under Good Laboratory Practice (GLP) conditions prior to administration into humans. To ensure product efficacy, however, it is essential that these standardized production procedures do not compromise therapeutic efficacy. The fate of modified MSCs upon intravenous injection is also uncertain, as previous trials of unmodiﬁed MSCs have achieved limited efﬁcacy owing to their quick elimination from circulation. Therefore, to achieve significant functional beneﬁts, this strategy requires a deﬁned selection of the number and type of stem cells to be delivered, an explicit vector application method, and fixed transduction efﬁciency and time of administration. In addition, the design of novel bioactive materials such as three-dimensional spheroids and nano-active scaffolds to bolster stem cell survival, signaling, and function at the target site can also help to increase the cost-effectiveness of the applications of modiﬁed MSCs for tissue repair.

At present it remains unclear as to whether it will be legally permissible to utilize genetically modiﬁed MSCs for clinical treatment. The potential consequences of utilizing such cells in humans are not well understood, and as such the safety of these approaches needs to be more thoroughly examined in animal model systems in order to identify means overcoming any potential safety issues. In addition, many of the ethical issues associated with genetically-modiﬁed MSC research are similar to those arising in other MSC-based interventions. Efforts to address these issues typically focus upon minimizing the risk of harm, emphasizing the importance of informed consent and information disclosure, reducing the potential for overpromising, limiting excessive expectations and therapeutic misconceptions, and avoiding pressure from commercial entities and disease constituencies to move quickly into the clinic. In addition, justice is a necessary consideration given that stem cell interventions can be extraordinary costly and labor-intensive, as can many other novel biotechnologies. Justice necessitates that additional attention be paid to the cost of genetically modiﬁed MSC interventions in an effort to make them available, effective, and safe, with the goal of reducing unfair disparities in treatment accessibility. These ethical considerations continue to provide crucial guidance for the clinical application of these approaches not only for the trials speciﬁcally considered, but also for investigators exploring new translational medicine pathways.

Current Challenges and Future Prospects

The therapeutic utility of GF gene-modiﬁed MSCs has been a focus of increasing research interest in recent years owing to their enhanced ability to suppress inﬂammation, home to target tissues, regulate immune responses, and facilitate tissue repair. Several preclinical and clinical...
studies have utilized MSC-based therapeutic strategies for treating a range of disorders and injuries. While efforts to modify MSCs to overexpress defined GFs are still in their early stages and are far from clinical application, although they offer a potentially ideal means of directed tissue regeneration. MSCs alone are limited in their ability to home to and survive in injured tissues, making the modification of MSCs to express such GF genes vital in order to facilitate more robust regenerative medicine approaches. While the outcomes of many of the studies reported in this review are promising, there remain many challenges which must be overcome. These include the need to optimize delivery strategies in human patients while simultaneously preventing immunogenicity or tumor formation. Preclinical findings highlight the safety and therapeutic efficacy of these GF-modified MSCs for the treatment of tissue damage.

In addition, large-scale, multi-center clinical trials are needed to conclusively demonstrate the long-term beneficial effects of such therapies. Further ongoing clinical studies and efforts to demonstrate the long-term beneficial effects will help to ensure that these promising therapeutic tools soon become available to patients as a novel and efficacious form of regenerative medicine.

Acknowledgments
The authors would like to thank the Jilin Scientific and Technological Development Program and the Interdisciplinary Research Funding Program for PhD Students of Jilin University, for their support in developing this paper.

Data Sharing Statement
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Funding
This study was supported by Jilin Scientific and Technological Development Program [grant number 20190304041YY] and the Interdisciplinary Research Funding Program for PhD Students of Jilin University [grant number 10183201849].

Disclosure
The authors report no conflicts of interest in this work.

References
1. Rajabzadeh N, Fathi E, Farahzadi R. Stem cell-based regenerative medicine. Stem Cell Invest. 2019;6:19. doi:10.21037/sci
2. Corey S, Bonsack B, Borlongan CV. Stem cell-based regenerative medicine for neurological disorders: a special tribute to Dr. Teng Ma. Brain Circ. 2019;5(3):97–100. doi:10.4103/bc.bc_39_19
3. Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-articular injection of autologous adipose tissue-dervied mesenchymal stem cells for the treatment of knee osteoarthritis: a phase Ib, randomized, placebo-controlled clinical trial. Stem Cells Transl Med. 2019;8(6):504–511. doi:10.1002/sctm.18-0122
4. Khan S, Mafi P, Mafi R, Khan W. A systematic review of mesenchymal stem cells in spinal cord injury, intervertebral disc repair and spinal fusion. Curr Stem Cell Res Ther. 2018;13(4):316–323. doi:10.2174/1574888X11666170907120030
5. Jayaram P, Ikpeama U, Rothenberg JB, Malanga GA. Bone marrow-derived and adipose-derived mesenchymal stem cell therapy in primary knee osteoarthritis: a narrative review. PM R. 2019;11(2):177–191. doi:10.1016/j.pmrj.2018.06.019
6. Qazi TH, Duda GN, Ort MJ, Perka C, Geissler S, Winkler T. Cell therapy to improve regeneration of skeletal muscle injuries. J Cachexia Sarcopenia Muscle. 2019;10(3):501–516. doi:10.1002/jcem.12416
7. Lemeche H, Voronina N, Steinhoff G, David R. Recent progress in stem cell modification for cardiac regeneration. Stem Cells Int. 2018;2018:1909346.
8. Grimm D, Egli M, Kruger M, et al. Tissue engineering under microgravity conditions-use of stem cells and specialized cells. Stem Cells Dev. 2018;27(12):787–804.
9. Madrigal M, Rao KS, Riordan NH. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J Transl Med. 2014;12:260.
10. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and hematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):829–834. doi:10.1038/nature09262
11. Rodrigues M, Griffith LG, Wells A. Growth factor regulation of proliferation and survival of multipotential stromal cells. Stem Cell Res Ther. 2010;1(4):32. doi:10.1186/scrt32
12. Hu MS, Borrelli MR, Lorenz HP, Longaker MT, Wan DC. Mesenchymal stromal cells and cutaneous wound healing: a comprehensive review of the background, role, and therapeutic potential. Stem Cells Int. 2018;2018:6901983. doi:10.1155/2018/6901983
13. Shafei AE, Ali MA, Ghanem HG, et al. Mesenchymal stem cell therapy: a promising cell-based therapy for treatment of myocardial infarction. J Gene Med. 2017;19:12. doi:10.1002/jgm.2995
14. Liu F, Qiu H, Xue M, et al. MSC-secreted TGF-beta regulates lipopolysaccharide-stimulated macrophage M2-like polarization via the Akt/FoxO1 pathway. Stem Cell Res Ther. 2019;10(1):345. doi:10.1186/s13287-019-1447-y
15. Wu R, Liu C, Deng X, Chen L, Hao S, Ma L. Enhanced alleviation of aGVHD by TGF-beta1-modified mesenchymal stem cells in mice through shifting MPhi into M2 phenotype and promoting the differentiation of Treg cells. J Cell Mol Med. 2019.
16. Zhang B, Wang M, Gong A, et al. HucMSC-exosome-med-Wnt4 signaling is required for cutaneous wound healing. Stem Cells. 2015;33(7):2158–2168. doi:10.1002/stem.1771
17. Furuta T, Miyaki S, Ishitobi H, et al. Mesenchymal stem cell-derived exosomes promote fracture healing in a mouse model. Stem Cells Transl Med. 2016;5(12):1620–1630. doi:10.5966/sctm.2015-0285
18. Wang LS, Wang H, Zhang QL, Yang ZJ, Kong FX, Wu CT. Hepatocyte growth factor gene therapy for ischemic diseases. Hum Gene Ther. 2018;29(4):413–423. doi:10.1089/hum.2017.217
Arthur A, Cakouros D, Cooper L, et al. Twist-1 enhances bone

Skelet Muscle Biomaterials 2005:

doi:10.1080/14653240802474307

20. Luo CH, Lin KJ, Chiu HY, et al. Improved chondrogenesis and engineered cartilage formation from TGF-beta3-expressing adipose-derived stem cells cultured in the rotating-shaft bioreactor. Tissue Eng Part A 2012;18(19–20):2114–2124. doi:10.1089/ten.tea.2012.0010

21. Lo WH, Hwang SM, Chuang CK, Chen CY, Hu YC. Development of a hybrid baculoviral vector for sustained transgene expression. Mol Ther 2009;17(4):658–666. doi:10.1038/m.2009.13

22. He CX, Zhang TY, Miao PH, et al. TGF-beta1 gene-engineered mesenchymal stem cells induce rat cartilage regeneration using nonviral gene vector. Biotechnol Appl Biochem. 2012;59(3):163–169. doi:10.1002/bab.10186

23. Tan Z, Zhao Q, Gong P, et al. Research on promoting periodontal regeneration with human basic fibroblast growth factor-modified bone marrow mesenchymal stromal cell gene therapy. Cytotherapy. 2009;11(3):317–325. doi:10.1080/14653240902824755

24. Gandra N, Wang DD, Zhu Y, Mao C. Virus-mimetic cytoplasm-cleavable magnetic/silica nanoclusters for enhanced gene delivery to mesenchymal stem cells. Angew Chem Int Ed Engl. 2013;52(43):11278–11281. doi:10.1002/anie.201301113

25. Mun JY, Shin KK, Kwon O, Lim YT, Oh DB. Minicircle microporation-based non-viral gene delivery improved the targeting of mesenchymal stem cells to an injury site. Biomaterials. 2016;101:310–320. doi:10.1016/j.biomaterials.2016.05.057

26. Hubbs AF, Mercer RR, Benovic SA, et al. Nanotoxicology - a pathologist’s perspective. Toxicol Pathol. 2011;39(2):301–324. doi:10.1177/0192623310390705

27. Norppa H, Catalán J, Falck G, Hannukainen K, Siivola K, Savolainen K. Nano-specific genotoxic effects. J Biomed Nanotechnol. 2011;7(1):19. doi:10.1166/jbn.2011.1179

28. Fierro FA, Kalomoiris S, Sondergaard CS, Nolta JA. Effects on prevention from left ventricular remodelling and functional improvement of a hybrid baculoviral vector for sustained transgene expression of a hybrid baculoviral vector for sustained transgene expression. Cell Biochem Funct. 2011;29(11):1727–1737. doi:10.1002/cbf.v30.7

29. Chen YA, Qian H, Zhu W, et al. Hepatocyte growth factor mod- ification promotes the amelioration effects of human umbilical cord mesenchymal stem cells on rat acute kidney injury. Stem Cells Dev. 2011;20(1):103–113. doi:10.1089/scd.2009.0495

30. González MN, de Mello W, Butler-Browne GS, et al. HGF potentiates extracellular matrix-driven migration of human myoblasts: involvement of matrix metalloproteinases and MAPK/ERK pathway. Skelet Muscle. 2017;7(1):20. doi:10.1186/s13395-017-0138-6

31. Wang SX, Qin X, Sun DD, et al. Effects of hepatocyte growth factor overexpressed bone marrow-derived mesenchymal stem cells on prevention from left ventricular remodelling and functional improvement in injured rat hearts. Cell Biochem Funct. 2012;30(7):574–581. doi:10.1002/cbf.v30.7

32. Zhao MZ, Nonoguchi N, Ikeda N, et al. Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab. 2006;26(9):1176–1188. doi:10.1038/sj.jcbfm.9600273
Nie et al.

54. Moon HH, Joo MK, Mok H, et al. MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine. *Biomaterials*. 2014;35 (5):1744–1754. doi:10.1016/j.biomaterials.2013.11.019

55. Yanfu H, Ran T, Yanqing H, et al. Microencapsulated VEGF gene-modified umbilical cord mesenchymal stromal cells promote the vascularization of tissue-engineered dermis: an experimental study. *Cytotherapy*. 2014;16(2):160–169. doi:10.1016/j.jcyt.2013.10.014

56. Lee JK, Setyawati MI, Peng F, Leong DT, Ho HK. Angiopoietin-1 accelerates restoration of endothelial cell barrier integrity from nanoparticle-induced leakiness. *Nanotoxicology*. 2019;13 (5):682–700. doi:10.1080/17435390.2019.1571646

57. Sun L, Cui M, Wang Z, et al. Mesenchymal stem cells modified with angiopoietin-1 improve remodeling in a rat model of acute myocardial infarction. *Biochem Biophys Res Commun*. 2007;357 (3):779–784. doi:10.1016/j.bbrc.2007.04.010

58. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. *PLoS Med*. 2007;4 (9):e269. doi:10.1371/journal.pmed.0040269

59. Xu J, Qu J, Cao L, et al. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. *J Pathol*. 2008;214(4):472–481. doi:10.1002/path.2302

60. Li Y, Zheng L, Xu X, et al. Mesenchymal stem cells modified with angiopoietin-1 gene promote wound healing. *Stem Cell Res Ther*. 2013;4(5):113. doi:10.1186/scrt324

61. Schubitz WR, Sommer C, Zoder W, Kiessling M, Schwangner M, Schwab S. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. *Stroke*. 2000;31(9):2212–2217. doi:10.1161/01.STR.31.9.2212

62. Fang Z, Yao W, Deng Q, Zhang X, Zhang J. Protective effects of BDNF overexpression bone marrow stromal cell transplantation in rat models of traumatic brain injury. *J Mol Neurosci*. 2013;49 (2):409–416. doi:10.1007/s12031-012-9908-0

63. Kurouzumi K, Nakamura K, Tamiya T, et al. BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. *Mol Ther*. 2004;9(2):189–197.

64. Li WJ, Tuli R, Okafor C, et al. A three-dimensional nanofibrous scaffold for cartilage tissue engineering using human mesenchymal stem cells. *Biomaterials*. 2005;26(6):599–609.

65. Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. *Shock*. 2010;33(1):24–30.

66. Huang AH, Motlekar NA, Stein A, Diamond SL, Shore EM, Mauck RL. High-throughput screening for modulators of mesenchymal stem cell chondrogenesis. *Ann Biomed Eng*. 2008;36 (11):1909–1921.

67. Scioli MG, Cervelli V, Arcuri G, et al. High insulin-induced down-regulation of Erk-1/IGF-1R/FGFR-1 signaling is required for oxidative stress-mediated apoptosis of adipose-derived stem cells. *J Cell Physiol*. 2014;229(12):2077–2087.

68. Savi M, Bocchi L, Fiumana E, et al. Enhanced engraftment and repairing ability of human adipose-derived stem cells, conveyed by pharmacologically active microcarriers continuously releasing HGF and IGF-1, in healing myocardial infarction in rats. *J Biomed Mater Res A*. 2015;103(9):3012–3025.

69. Gomez-Mauricio G, Moscoso I, Martin-Cancho MF, et al. Combined administration of mesenchymal stem cells overexpressing IGF-1 and HGF enhances neovascularization but moderately improves cardiac regeneration in a porcine model. *Stem Cell Res Ther*. 2016;7(1):94.

70. Chen B, Li Q, Zhao B, Wang Y. Stem cell-derived extracellular vesicles as a novel potential therapeutic tool for tissue repair. *Stem Cells Transl Med*. 2017;6(9):1753–1758.

71. Choi JS, Yoon HI, Lee KS, et al. Exosomes from differentiating human skeletal muscle cells trigger myogenesis of stem cells and provide biochemical cues for skeletal muscle regeneration. *J Control Release*. 2016;222:107–115.

72. Tsuij K, Kitamura S, Wada J. Immunomodulatory and regenerative effects of mesenchymal stem cell-derived extracellular vesicles in renal diseases. *Int J Mol Sci*. 2020;21:3.

73. Tan CY, Lai RC, Wong W, Dan YY, Lim S-K, Ho HK. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. *Stem Cell Res Ther*. 2014;5(3):76.

74. Choi JS, Yoon HI, Lee KS, et al. Exosomes from differentiating human skeletal muscle cells trigger myogenesis of stem cells and provide biochemical cues for skeletal muscle regeneration. *J Control Release*. 2016;222:107–115.

75. Shafei AE, Ali MA, Ghanem HG, et al. Mesenchymal stem cells therapy: a promising cell based therapy for treatment of myocardial infarction. *J Gene Med*. 2017;19:12. doi:10.1002/jgm.2995

76. Ikeda N, Nonoguchi N, Zhao MZ, et al. Bone marrow stromal cells that enhanced fibroblast growth factor-2 secretion by herpes simplex virus vector improve neurological outcome after transient focal cerebral ischemia in rats. *Stroke*. 2005;36(12):2725–2730.

77. Pollock K, Dahlenburg H, Nelson H, et al. Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington’s disease mouse models. *Mol Ther*. 2016;24(5):965–977.

78. Zhao GY, Cui L, Gao J, Dai RT, Zhang P. Study on the levels of DA and metabolite in striatum in rats with Parkinson’s disease treated by BDNF gene modified bone mesenchymal stem cells. *Zhongguo Ying Yang Sheng Li Xue Za Zhi*. 2013;29(1):82–85.

79. Chen H, Xia R, Li Z, et al. Mesenchymal stem cells combined with hepatocyte growth factor therapy for attenuating ischaemic myocardial fibrosis: assessment using multimodal molecular imaging. *Sci Rep*. 2016;6:33700.

80. Gao F, He T, Wang H, et al. A promising strategy for the treatment of ischemic heart disease: mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. *Can J Cardiol*. 2007;23(11):891–898.

81. Li Z, Mei J, Zhang B. Cell transplantation of 5-aza cytidine induced bone marrow stromal cells transfected by angiogenin gene ex vivo into infarcted myocardium, an experimental study. *Zhonghua Yi Xue Za Zhi*. 2002;82(19):1319–1323.

82. Fan L, Lin C, Zhuo S, et al. Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. *Eur J Heart Fail*. 2009;11(11):1023–1030.

83. Wang H, Sun RT, Li Y, et al. HGF Gene Modification in mesenchymal stem cells reduces radiation-induced intestinal injury by modulating immunity. *PLoS One*. 2015;10(5):e0124420.

84. Hao L, Wang J, Zou Z, et al. Transplantation of BMSCs expressing hPDGF-A-hBD2 promotes wound healing in rats with combined radiation-wound injury. *Gene Ther*. 2009;16(1):34–42.

85. Xue Z, Li X, Lu Y, et al. Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. *Mol Ther*. 2013;21 (2):456–465.

86. Huang JH, Surgery BDO, Hospital D, et al. Intravenous injection of nerve growth factor gene-modified bone marrow stromal stem cells on the apoptosis of the mouse hepatic cells induced by radiation. *J Clin Rehab Tissue Eng Res*. 2008;12(38):7503–7506.

87. Kumar S, Nagy TR, Ponnazhagan S. Therapeutic potential of genetically modified adult stem cells for osteopenia. *Gene Ther*. 2010;17(1):105–116.
88. Dulamea AO. The potential use of mesenchymal stem cells in stroke therapy—From bench to bedside. J Neurol Sci 2015;352 (1–2):1–11.

89. Su YR, Wang J, Wu JJ, Chen Y, Jiang YP. Overexpression of lentivirus-mediated glial cell line-derived neurotrophic factor in bone marrow stromal cells and its neuroprotection for the PC12 cells damaged by lacticacitin. Neurosci Bull. 2007;23(2):67–74.

90. Lundberg J, Jussing E, Liu Z, et al. Safety of intra-arterial injection with tumor-activated T cells to the rabbit brain evaluated by MRI and SPECT/CT. Cell Transplant. 2017;26(2):283–292.

91. Bhatia V, Gupta V, Khurana D, Sharma RR, Khandelwal N. Randomized assessment of the safety and efficacy of intra-arterial infusion of autologous stem cells in subacute ischemic stroke. AJNR. 2018;39(5):899–904.

92. Feng CJ, Perng CK, Lin CH, Tsai CH, Huang PH, Ma H. Intra-arterial injection of human adipose-derived stem cells improves viability of the random component of axial skin flaps in nude mice. J Plast Reconstr Aesthet Surg. 2020;73(3):598–607.

93. Di Spigna G, Iannone M, Lodogana P, et al. Human cardiac multipotent adult stem cells in 3D matrix: new approach of tissue engineering in cardiac regeneration post-infarction. J Biol Regul Homeost Agents. 2017;31(4):911–921.

94. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol. 2005;46(7):1339–1350.

95. Liu N, Zhang Y, Fan L, et al. Effects of transplantation with bone marrow-derived mesenchymal stem cells modified by Survivin on experimental stroke in rats. J Transl Med. 2011;9:105.

96. Li W, Ma N, Ong LL, et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells. 2007;25(8):2118–2127.

97. Mangi AA, Noiseux N, Kong DL, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003;9(9):1195–1201.

98. Gneecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20(6):661–669.

99. Gallo S, Sala V, Gatti S, Cerepaldi T. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. Clin Sci (Lond). 2015;129(12):1173–1193.

100. Forte G, Minieri M, Cossa P, et al. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells. 2006;24(1):23–33. doi:10.1634/stemcells.2004-0176

101. Lu F, Zhao X, Wu J, et al. MSCs transfected with hepatocyte growth factor or vascular endothelial growth factor improve cardiac function in the infarcted porcine heart by increasing angiogenesis and reducing fibrosis. Int J Cardiol. 2013;167(6):2524–2532. doi:10.1016/j.ijcard.2012.06.052

102. Gomez-Mauricio G, Moscoso I, Martin-Cancho MF, et al. Combined administration of mesenchymal stem cells overexpressing IGF-1 and HGF enhances neovascularization but moderately improves cardiac regeneration in a porcine model. Stem Cell Res Ther. 2016;7(1):94. doi:10.1186/s13287-016-0350-z

103. Yang ZJ, Ma DC, Wang W, et al. Experimental study of bone marrow-derived mesenchymal stem cells combined with hepatocyte growth factor transplantation via noninfarct-relative artery in acute myocardial infarction. Gene Ther. 2006;13(22):1564–1568. doi:10.1016/j.ymgth.2006.03.020

104. Zhang J, Wang LL, Du W, et al. Hepatocyte growth factor modification enhances the anti-arrhythmic properties of human bone marrow-derived mesenchymal stem cells. PLoS One. 2014;9(10):e111246. doi:10.1371/journal.pone.0111246

105. Laddha AP, Kulkarni YA. VEGF and FGF-2: promising targets for the treatment of respiratory disorders. Respir Med. 2019;156:33–46. doi:10.1016/j.rmed.2019.08.003

106. Giri TK, Alexander A, Agrawal M, Saraf S, Saraf S. Ajazuddin. Current status of stem cell therapies in tissue repair and regeneration. Curr Stem Cell Res Ther. 2019;14(2):117–126. doi:10.2174/1574888X13666180521033831

107. Kong F, Shi X, Xiao F, et al. Transplantation of HGF modified dental pulp stem cells prevents bone loss in the early phase of ovariectomized osteoporosis. Hum Gene Ther. 2018;29(2):271–282. doi:10.1089/hum.2017.091

108. Zhang J, Chen J. Bone tissue regeneration - application of mesenchymal stem cells and cellular and molecular mechanisms. Curr Stem Cell Res Ther. 2017;12(5):357–364. doi:10.2174/1574888X1156616092121555

109. Pacelli S, Basu S, Whitlow J, et al. Strategies to develop endogenous stem cell-recruiting bioactive materials for tissue repair and regeneration. Adv Drug Deliv Rev. 2017;120:50–70. doi:10.1016/j.addr.2017.07.011

110. Brunger JM, Hyuhn NP, Guenther CM, et al. Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage. Proc Natl Acad Sci U S A. 2014;111(9):E798–E806. doi:10.1073/pnas.1321744111

111. Wang T, Liao T, Wang H, Deng W, Yu D. Transplantation of bone marrow stromal cells overexpressing human vascular endothelial growth factor 165 enhances tissue repair in a rat model of radiation-induced injury. Chin Med J (Engl). 2014;127(6):1093–1099.

112. Hu S, Chen Y, Li L, et al. Effects of adenovirus-mediated delivery of the human hepatocyte growth factor gene in experimental radiation-induced heart disease. Int J Radiat Oncol Biol Phys. 2009;75(5):1537–1544. doi:10.1016/j.ijrobp.2009.07.1697

113. Li Q, Sun H, Xiao F, et al. Protection against radiation-induced hematopoietic damage in bone marrow by hepatocyte growth factor gene transfer. Int J Radiat Biol. 2014;90(1):36–44. doi:10.3109/09553002.2014.87294

114. Zhang J, Zhou S, Zhou Y, et al. Hepatocyte growth factor gene-modified adipose-derived mesenchymal stem cells ameliorate radiation induced liver damage in a rat model. PLoS One. 2014;9(12):e114670. doi:10.1371/journal.pone.0114670

115. Chen S, Chen X, Wu X, et al. Hepatocyte growth factor-modified mesenchymal stem cells improve ischemia/reperfusion-induced acute lung injury in rats. Gene Ther. 2017;24(1):1–11. doi:10.1038/gt.2016.64

116. Shao Y, Shen J, Zhou F, He D. Mesenchymal stem cells overexpressing Ang1 attenuates phagene-induced acute lung injury in rats. Inhal Toxicol. 2018;30(7–8):313–320. doi:10.1080/08958378.2018.1521483

117. Sage EK, Thakrar RM, Janes SM. Genetically modified mesenchymal stromal cells in cancer therapy. Cytotechnology. 2016;18(11):1435–1445. doi:10.1007/jcyt.2016.09.003

118. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(6):1590–1598. doi:10.1378/chest.12-2094

119. Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Resp Med. 2015;3(1):24–32. doi:10.1016/s2212-6779(14)70291-7

120. Ripa RS, Wang Y, Jorgensen E, Johnsen HE, Hesse B, Kastrup J. Intramyocardial injection of mesenchymal stromal growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischemic heart disease. European Heart Journal. 2006;27(15):1785–1792.

121. Wheelock V, Tempkin T, Duffy A, et al. PRE-CELL: clinical and novel biomarker measures of disease progression in a lead-in-observational study for a planned phase 1 trial of genetically modified mesenchymal stem cells over-expressing BDNF in patients with Huntington’s disease (S25.004). Neurology. 2016;86(16 Supplement):S25.004.
122. Deng P, Torrest A, Pollock K, et al. Clinical trial perspective for adult and juvenile Huntington’s disease using genetically-engineered mesenchymal stem cells. *Neural Regen Res.* 2016;11(05):702–705. doi:10.4103/1673-5374.182682

123. Daley GQ, Hyun I, Apperley JF, et al. Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines. *Stem Cell Reports.* 2016;6(6):787–797. doi:10.1016/j.stemcr.2016.05.001

124. Munoz Ruiz M, Regueiro JR. New tools in regenerative medicine: gene therapy. *Adv Exp Med Biol.* 2012;741:254–275.

125. Poulos J. The limited application of stem cells in medicine: a review. *Stem Cell Res Ther.* 2018;9(1):1. doi:10.1186/s13287-017-0735-7

126. Imamura A, Kajiya H, Fujisaki S, et al. Three-dimensional spheroids of mesenchymal stem/stromal cells promote osteogenesis by activating stemness and Wnt/beta-catenin. *Biochem Biophys Res Commun.* 2020;523(2):458–464. doi:10.1016/j.bbrc.2019.12.066

127. King NM, Perrin J. Ethical issues in stem cell research and therapy. *Stem Cell Res Ther.* 2014;5(4):85. doi:10.1186/s13287-013-0074-7